img

Global Ulcerative Colitis Immunology Drugs Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Ulcerative Colitis Immunology Drugs Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

Ulcerative Colitis Immunology Drugs report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Ulcerative Colitis Immunology Drugs market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Rheumatoid Arthritis and Crohn's Disease(CD) are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Ulcerative Colitis Immunology Drugs industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Ulcerative Colitis Immunology Drugs key manufacturers include Janssen Biotech, Inc., Bristol-Myers Squibb Company, AbbVie Inc., UCBCares, AMGEN, Celltrion Healthcare, Biogen, Genentech USA, Inc. and ROCHE, etc. Janssen Biotech, Inc., Bristol-Myers Squibb Company, AbbVie Inc. are top 3 players and held % sales share in total in 2022.
Ulcerative Colitis Immunology Drugs can be divided into Adalimumab, Certolizumab Pegol, Tofacitinib and Etanercept, etc. Adalimumab is the mainstream product in the market, accounting for % sales share globally in 2022.
Ulcerative Colitis Immunology Drugs is widely used in various fields, such as Rheumatoid Arthritis, Crohn's Disease(CD), Ankylosing Spondylitis(AS) and Psoriasis(Ps), etc. Rheumatoid Arthritis provides greatest supports to the Ulcerative Colitis Immunology Drugs industry development. In 2022, global % sales of Ulcerative Colitis Immunology Drugs went into Rheumatoid Arthritis filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Ulcerative Colitis Immunology Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report



By Company


Janssen Biotech, Inc.
Bristol-Myers Squibb Company
AbbVie Inc.
UCBCares
AMGEN
Celltrion Healthcare
Biogen
Genentech USA, Inc.
ROCHE
Pfizer Inc.
Segment by Type
Adalimumab
Certolizumab Pegol
Tofacitinib
Etanercept
Golimumab
Abatacept
Infliximab
Others

Segment by Application


Rheumatoid Arthritis
Crohn's Disease(CD)
Ankylosing Spondylitis(AS)
Psoriasis(Ps)
Ulcerative Colitis(UC)

Segment by Region


North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Ulcerative Colitis Immunology Drugs market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Ulcerative Colitis Immunology Drugs, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Ulcerative Colitis Immunology Drugs industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Ulcerative Colitis Immunology Drugs in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Ulcerative Colitis Immunology Drugs introduction, etc. Ulcerative Colitis Immunology Drugs Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Ulcerative Colitis Immunology Drugs market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.

Table of Content

1 Ulcerative Colitis Immunology Drugs Market Overview
1.1 Ulcerative Colitis Immunology Drugs Product Overview
1.2 Ulcerative Colitis Immunology Drugs Market Segment by Type
1.2.1 Adalimumab
1.2.2 Certolizumab Pegol
1.2.3 Tofacitinib
1.2.4 Etanercept
1.2.5 Golimumab
1.2.6 Abatacept
1.2.7 Infliximab
1.2.8 Others
1.3 Global Ulcerative Colitis Immunology Drugs Market Size by Type
1.3.1 Global Ulcerative Colitis Immunology Drugs Market Size Overview by Type (2018-2034)
1.3.2 Global Ulcerative Colitis Immunology Drugs Historic Market Size Review by Type (2018-2024)
1.3.3 Global Ulcerative Colitis Immunology Drugs Forecasted Market Size by Type (2024-2034)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Ulcerative Colitis Immunology Drugs Sales Breakdown by Type (2018-2024)
1.4.2 Europe Ulcerative Colitis Immunology Drugs Sales Breakdown by Type (2018-2024)
1.4.3 Asia-Pacific Ulcerative Colitis Immunology Drugs Sales Breakdown by Type (2018-2024)
1.4.4 Latin America Ulcerative Colitis Immunology Drugs Sales Breakdown by Type (2018-2024)
1.4.5 Middle East and Africa Ulcerative Colitis Immunology Drugs Sales Breakdown by Type (2018-2024)
2 Global Ulcerative Colitis Immunology Drugs Market Competition by Company
2.1 Global Top Players by Ulcerative Colitis Immunology Drugs Sales (2018-2024)
2.2 Global Top Players by Ulcerative Colitis Immunology Drugs Revenue (2018-2024)
2.3 Global Top Players by Ulcerative Colitis Immunology Drugs Price (2018-2024)
2.4 Global Top Manufacturers Ulcerative Colitis Immunology Drugs Manufacturing Base Distribution, Sales Area, Product Type
2.5 Ulcerative Colitis Immunology Drugs Market Competitive Situation and Trends
2.5.1 Ulcerative Colitis Immunology Drugs Market Concentration Rate (2018-2024)
2.5.2 Global 5 and 10 Largest Manufacturers by Ulcerative Colitis Immunology Drugs Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Ulcerative Colitis Immunology Drugs as of 2022)
2.7 Date of Key Manufacturers Enter into Ulcerative Colitis Immunology Drugs Market
2.8 Key Manufacturers Ulcerative Colitis Immunology Drugs Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Ulcerative Colitis Immunology Drugs Status and Outlook by Region
3.1 Global Ulcerative Colitis Immunology Drugs Market Size and CAGR by Region: 2018 VS 2022 VS 2034
3.2 Global Ulcerative Colitis Immunology Drugs Historic Market Size by Region
3.2.1 Global Ulcerative Colitis Immunology Drugs Sales in Volume by Region (2018-2024)
3.2.2 Global Ulcerative Colitis Immunology Drugs Sales in Value by Region (2018-2024)
3.2.3 Global Ulcerative Colitis Immunology Drugs Sales (Volume & Value) Price and Gross Margin (2018-2024)
3.3 Global Ulcerative Colitis Immunology Drugs Forecasted Market Size by Region
3.3.1 Global Ulcerative Colitis Immunology Drugs Sales in Volume by Region (2024-2034)
3.3.2 Global Ulcerative Colitis Immunology Drugs Sales in Value by Region (2024-2034)
3.3.3 Global Ulcerative Colitis Immunology Drugs Sales (Volume & Value), Price and Gross Margin (2024-2034)
4 Global Ulcerative Colitis Immunology Drugs by Application
4.1 Ulcerative Colitis Immunology Drugs Market Segment by Application
4.1.1 Rheumatoid Arthritis
4.1.2 Crohn's Disease(CD)
4.1.3 Ankylosing Spondylitis(AS)
4.1.4 Psoriasis(Ps)
4.1.5 Ulcerative Colitis(UC)
4.2 Global Ulcerative Colitis Immunology Drugs Market Size by Application
4.2.1 Global Ulcerative Colitis Immunology Drugs Market Size Overview by Application (2018-2034)
4.2.2 Global Ulcerative Colitis Immunology Drugs Historic Market Size Review by Application (2018-2024)
4.2.3 Global Ulcerative Colitis Immunology Drugs Forecasted Market Size by Application (2024-2034)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Ulcerative Colitis Immunology Drugs Sales Breakdown by Application (2018-2024)
4.3.2 Europe Ulcerative Colitis Immunology Drugs Sales Breakdown by Application (2018-2024)
4.3.3 Asia-Pacific Ulcerative Colitis Immunology Drugs Sales Breakdown by Application (2018-2024)
4.3.4 Latin America Ulcerative Colitis Immunology Drugs Sales Breakdown by Application (2018-2024)
4.3.5 Middle East and Africa Ulcerative Colitis Immunology Drugs Sales Breakdown by Application (2018-2024)
5 North America Ulcerative Colitis Immunology Drugs by Country
5.1 North America Ulcerative Colitis Immunology Drugs Historic Market Size by Country
5.1.1 North America Ulcerative Colitis Immunology Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
5.1.2 North America Ulcerative Colitis Immunology Drugs Sales in Volume by Country (2018-2024)
5.1.3 North America Ulcerative Colitis Immunology Drugs Sales in Value by Country (2018-2024)
5.2 North America Ulcerative Colitis Immunology Drugs Forecasted Market Size by Country
5.2.1 North America Ulcerative Colitis Immunology Drugs Sales in Volume by Country (2024-2034)
5.2.2 North America Ulcerative Colitis Immunology Drugs Sales in Value by Country (2024-2034)
6 Europe Ulcerative Colitis Immunology Drugs by Country
6.1 Europe Ulcerative Colitis Immunology Drugs Historic Market Size by Country
6.1.1 Europe Ulcerative Colitis Immunology Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
6.1.2 Europe Ulcerative Colitis Immunology Drugs Sales in Volume by Country (2018-2024)
6.1.3 Europe Ulcerative Colitis Immunology Drugs Sales in Value by Country (2018-2024)
6.2 Europe Ulcerative Colitis Immunology Drugs Forecasted Market Size by Country
6.2.1 Europe Ulcerative Colitis Immunology Drugs Sales in Volume by Country (2024-2034)
6.2.2 Europe Ulcerative Colitis Immunology Drugs Sales in Value by Country (2024-2034)
7 Asia-Pacific Ulcerative Colitis Immunology Drugs by Region
7.1 Asia-Pacific Ulcerative Colitis Immunology Drugs Historic Market Size by Region
7.1.1 Asia-Pacific Ulcerative Colitis Immunology Drugs Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2034
7.1.2 Asia-Pacific Ulcerative Colitis Immunology Drugs Sales in Volume by Region (2018-2024)
7.1.3 Asia-Pacific Ulcerative Colitis Immunology Drugs Sales in Value by Region (2018-2024)
7.2 Asia-Pacific Ulcerative Colitis Immunology Drugs Forecasted Market Size by Region
7.2.1 Asia-Pacific Ulcerative Colitis Immunology Drugs Sales in Volume by Region (2024-2034)
7.2.2 Asia-Pacific Ulcerative Colitis Immunology Drugs Sales in Value by Region (2024-2034)
8 Latin America Ulcerative Colitis Immunology Drugs by Country
8.1 Latin America Ulcerative Colitis Immunology Drugs Historic Market Size by Country
8.1.1 Latin America Ulcerative Colitis Immunology Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
8.1.2 Latin America Ulcerative Colitis Immunology Drugs Sales in Volume by Country (2018-2024)
8.1.3 Latin America Ulcerative Colitis Immunology Drugs Sales in Value by Country (2018-2024)
8.2 Latin America Ulcerative Colitis Immunology Drugs Forecasted Market Size by Country
8.2.1 Latin America Ulcerative Colitis Immunology Drugs Sales in Volume by Country (2024-2034)
8.2.2 Latin America Ulcerative Colitis Immunology Drugs Sales in Value by Country (2024-2034)
9 Middle East and Africa Ulcerative Colitis Immunology Drugs by Country
9.1 Middle East and Africa Ulcerative Colitis Immunology Drugs Historic Market Size by Country
9.1.1 Middle East and Africa Ulcerative Colitis Immunology Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
9.1.2 Middle East and Africa Ulcerative Colitis Immunology Drugs Sales in Volume by Country (2018-2024)
9.1.3 Middle East and Africa Ulcerative Colitis Immunology Drugs Sales in Value by Country (2018-2024)
9.2 Middle East and Africa Ulcerative Colitis Immunology Drugs Forecasted Market Size by Country
9.2.1 Middle East and Africa Ulcerative Colitis Immunology Drugs Sales in Volume by Country (2024-2034)
9.2.2 Middle East and Africa Ulcerative Colitis Immunology Drugs Sales in Value by Country (2024-2034)
10 Company Profiles
10.1 Janssen Biotech, Inc.
10.1.1 Janssen Biotech, Inc. Company Information
10.1.2 Janssen Biotech, Inc. Introduction and Business Overview
10.1.3 Janssen Biotech, Inc. Ulcerative Colitis Immunology Drugs Sales, Revenue and Gross Margin (2018-2024)
10.1.4 Janssen Biotech, Inc. Ulcerative Colitis Immunology Drugs Products Offered
10.1.5 Janssen Biotech, Inc. Recent Development
10.2 Bristol-Myers Squibb Company
10.2.1 Bristol-Myers Squibb Company Company Information
10.2.2 Bristol-Myers Squibb Company Introduction and Business Overview
10.2.3 Bristol-Myers Squibb Company Ulcerative Colitis Immunology Drugs Sales, Revenue and Gross Margin (2018-2024)
10.2.4 Bristol-Myers Squibb Company Ulcerative Colitis Immunology Drugs Products Offered
10.2.5 Bristol-Myers Squibb Company Recent Development
10.3 AbbVie Inc.
10.3.1 AbbVie Inc. Company Information
10.3.2 AbbVie Inc. Introduction and Business Overview
10.3.3 AbbVie Inc. Ulcerative Colitis Immunology Drugs Sales, Revenue and Gross Margin (2018-2024)
10.3.4 AbbVie Inc. Ulcerative Colitis Immunology Drugs Products Offered
10.3.5 AbbVie Inc. Recent Development
10.4 UCBCares
10.4.1 UCBCares Company Information
10.4.2 UCBCares Introduction and Business Overview
10.4.3 UCBCares Ulcerative Colitis Immunology Drugs Sales, Revenue and Gross Margin (2018-2024)
10.4.4 UCBCares Ulcerative Colitis Immunology Drugs Products Offered
10.4.5 UCBCares Recent Development
10.5 AMGEN
10.5.1 AMGEN Company Information
10.5.2 AMGEN Introduction and Business Overview
10.5.3 AMGEN Ulcerative Colitis Immunology Drugs Sales, Revenue and Gross Margin (2018-2024)
10.5.4 AMGEN Ulcerative Colitis Immunology Drugs Products Offered
10.5.5 AMGEN Recent Development
10.6 Celltrion Healthcare
10.6.1 Celltrion Healthcare Company Information
10.6.2 Celltrion Healthcare Introduction and Business Overview
10.6.3 Celltrion Healthcare Ulcerative Colitis Immunology Drugs Sales, Revenue and Gross Margin (2018-2024)
10.6.4 Celltrion Healthcare Ulcerative Colitis Immunology Drugs Products Offered
10.6.5 Celltrion Healthcare Recent Development
10.7 Biogen
10.7.1 Biogen Company Information
10.7.2 Biogen Introduction and Business Overview
10.7.3 Biogen Ulcerative Colitis Immunology Drugs Sales, Revenue and Gross Margin (2018-2024)
10.7.4 Biogen Ulcerative Colitis Immunology Drugs Products Offered
10.7.5 Biogen Recent Development
10.8 Genentech USA, Inc.
10.8.1 Genentech USA, Inc. Company Information
10.8.2 Genentech USA, Inc. Introduction and Business Overview
10.8.3 Genentech USA, Inc. Ulcerative Colitis Immunology Drugs Sales, Revenue and Gross Margin (2018-2024)
10.8.4 Genentech USA, Inc. Ulcerative Colitis Immunology Drugs Products Offered
10.8.5 Genentech USA, Inc. Recent Development
10.9 ROCHE
10.9.1 ROCHE Company Information
10.9.2 ROCHE Introduction and Business Overview
10.9.3 ROCHE Ulcerative Colitis Immunology Drugs Sales, Revenue and Gross Margin (2018-2024)
10.9.4 ROCHE Ulcerative Colitis Immunology Drugs Products Offered
10.9.5 ROCHE Recent Development
10.10 Pfizer Inc.
10.10.1 Pfizer Inc. Company Information
10.10.2 Pfizer Inc. Introduction and Business Overview
10.10.3 Pfizer Inc. Ulcerative Colitis Immunology Drugs Sales, Revenue and Gross Margin (2018-2024)
10.10.4 Pfizer Inc. Ulcerative Colitis Immunology Drugs Products Offered
10.10.5 Pfizer Inc. Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Ulcerative Colitis Immunology Drugs Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Ulcerative Colitis Immunology Drugs Industrial Chain Analysis
11.4 Ulcerative Colitis Immunology Drugs Market Dynamics
11.4.1 Ulcerative Colitis Immunology Drugs Industry Trends
11.4.2 Ulcerative Colitis Immunology Drugs Market Drivers
11.4.3 Ulcerative Colitis Immunology Drugs Market Challenges
11.4.4 Ulcerative Colitis Immunology Drugs Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Ulcerative Colitis Immunology Drugs Distributors
12.3 Ulcerative Colitis Immunology Drugs Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer

List of Figure

List of Tables
Table 1. Major Company of Adalimumab
Table 2. Major Company of Certolizumab Pegol
Table 3. Major Company of Tofacitinib
Table 4. Major Company of Etanercept
Table 5. Major Company of Golimumab
Table 6. Major Company of Abatacept
Table 7. Major Company of Infliximab
Table 8. Major Company of Others
Table 9. Global Ulcerative Colitis Immunology Drugs Sales by Type 2018 VS 2022 VS 2034 (US$ Million)
Table 10. Global Ulcerative Colitis Immunology Drugs Sales by Type (2018-2024) & (K Pcs)
Table 11. Global Ulcerative Colitis Immunology Drugs Sales Market Share in Volume by Type (2018-2024)
Table 12. Global Ulcerative Colitis Immunology Drugs Sales by Type (2018-2024) & (US& Million)
Table 13. Global Ulcerative Colitis Immunology Drugs Market Share in Value by Type (2018-2024)
Table 14. Global Ulcerative Colitis Immunology Drugs Price by Type (2018-2024) & (USD/Pcs)
Table 15. Global Ulcerative Colitis Immunology Drugs Sales by Type (2024-2034) & (K Pcs)
Table 16. Global Ulcerative Colitis Immunology Drugs Sales Market Share in Volume by Type (2024-2034)
Table 17. Global Ulcerative Colitis Immunology Drugs Sales by Type (2024-2034) & (US$ Million)
Table 18. Global Ulcerative Colitis Immunology Drugs Sales Market Share in Value by Type (2024-2034)
Table 19. Global Ulcerative Colitis Immunology Drugs Price by Type (2024-2034) & (USD/Pcs)
Table 20. North America Ulcerative Colitis Immunology Drugs Sales by Type (2018-2024) & (K Pcs)
Table 21. North America Ulcerative Colitis Immunology Drugs Sales by Type (2018-2024) & (US$ Million)
Table 22. Europe Ulcerative Colitis Immunology Drugs Sales (K Pcs) by Type (2018-2024)
Table 23. Europe Ulcerative Colitis Immunology Drugs Sales by Type (2018-2024) & (US$ Million)
Table 24. Asia-Pacific Ulcerative Colitis Immunology Drugs Sales (K Pcs) by Type (2018-2024)
Table 25. Asia-Pacific Ulcerative Colitis Immunology Drugs Sales by Type (2018-2024) & (US$ Million)
Table 26. Latin America Ulcerative Colitis Immunology Drugs Sales (K Pcs) by Type (2018-2024)
Table 27. Latin America Ulcerative Colitis Immunology Drugs Sales by Type (2018-2024) & (US$ Million)
Table 28. Middle East and Africa Ulcerative Colitis Immunology Drugs Sales (K Pcs) by Type (2018-2024)
Table 29. Middle East and Africa Ulcerative Colitis Immunology Drugs Sales by Type (2018-2024) & (US$ Million)
Table 30. Global Ulcerative Colitis Immunology Drugs Sales by Company (2018-2024) & (K Pcs)
Table 31. Global Ulcerative Colitis Immunology Drugs Sales Share by Company (2018-2024)
Table 32. Global Ulcerative Colitis Immunology Drugs Revenue by Company (2018-2024) & (US$ Million)
Table 33. Global Ulcerative Colitis Immunology Drugs Revenue Share by Company (2018-2024)
Table 34. Global Market Ulcerative Colitis Immunology Drugs Price by Company (2018-2024) & (USD/Pcs)
Table 35. Global Ulcerative Colitis Immunology Drugs Top Manufacturers Manufacturing Base Distribution and Sales Area
Table 36. Global Ulcerative Colitis Immunology Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 37. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Ulcerative Colitis Immunology Drugs as of 2022)
Table 38. Date of Key Manufacturers Enter into Ulcerative Colitis Immunology Drugs Market
Table 39. Key Manufacturers Ulcerative Colitis Immunology Drugs Product Type
Table 40. Mergers & Acquisitions, Expansion Plans
Table 41. Global Ulcerative Colitis Immunology Drugs Market Size Comparison by Region (US$ Million): 2018 VS 2022 VS 2034
Table 42. Global Ulcerative Colitis Immunology Drugs Sales by Region (2018-2024) & (K Pcs)
Table 43. Global Ulcerative Colitis Immunology Drugs Sales Market Share in Volume by Region (2018-2024)
Table 44. Global Ulcerative Colitis Immunology Drugs Sales by Region (2018-2024) & (US$ Million)
Table 45. Global Ulcerative Colitis Immunology Drugs Sales Market Share in Value by Region (2018-2024)
Table 46. Global Ulcerative Colitis Immunology Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 47. Global Ulcerative Colitis Immunology Drugs Sales by Region (2024-2034) & (K Pcs)
Table 48. Global Ulcerative Colitis Immunology Drugs Sales Market Share in Volume by Region (2024-2034)
Table 49. Global Ulcerative Colitis Immunology Drugs Sales by Region (2024-2034) & (US$ Million)
Table 50. Global Ulcerative Colitis Immunology Drugs Sales Market Share in Value by Region (2024-2034)
Table 51. Global Ulcerative Colitis Immunology Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2024-2034)
Table 52. Global Ulcerative Colitis Immunology Drugs Sales by Application: 2018 VS 2022 VS 2034 (US$ Million)
Table 53. Global Ulcerative Colitis Immunology Drugs Sales by Application (2018-2024) & (K Pcs)
Table 54. Global Ulcerative Colitis Immunology Drugs Sales Market Share in Volume by Application (2018-2024)
Table 55. Global Ulcerative Colitis Immunology Drugs Sales by Application (2018-2024) & (US$ Million)
Table 56. Global Ulcerative Colitis Immunology Drugs Sales Market Share in Value by Application (2018-2024)
Table 57. Global Ulcerative Colitis Immunology Drugs Price by Application (2018-2024) & (USD/Pcs)
Table 58. Global Ulcerative Colitis Immunology Drugs Sales by Application (2024-2034) & (K Pcs)
Table 59. Global Ulcerative Colitis Immunology Drugs Sales Market Share in Volume by Application (2024-2034)
Table 60. Global Ulcerative Colitis Immunology Drugs Sales by Application (2024-2034) & (US$ Million)
Table 61. Global Ulcerative Colitis Immunology Drugs Sales Market Share in Value by Application (2024-2034)
Table 62. Global Ulcerative Colitis Immunology Drugs Price by Application (2024-2034) & (USD/Pcs)
Table 63. North America Ulcerative Colitis Immunology Drugs Sales by Application (2018-2024) (K Pcs)
Table 64. North America Ulcerative Colitis Immunology Drugs Sales by Application (2018-2024) & (US$ Million)
Table 65. Europe Ulcerative Colitis Immunology Drugs Sales by Application (2018-2024) (K Pcs)
Table 66. Europe Ulcerative Colitis Immunology Drugs Sales by Application (2018-2024) & (US$ Million)
Table 67. Asia-Pacific Ulcerative Colitis Immunology Drugs Sales by Application (2018-2024) (K Pcs)
Table 68. Asia-Pacific Ulcerative Colitis Immunology Drugs Sales by Application (2018-2024) & (US$ Million)
Table 69. Latin America Ulcerative Colitis Immunology Drugs Sales by Application (2018-2024) (K Pcs)
Table 70. Latin America Ulcerative Colitis Immunology Drugs Sales by Application (2018-2024) & (US$ Million)
Table 71. Middle East and Africa Ulcerative Colitis Immunology Drugs Sales by Application (2018-2024) (K Pcs)
Table 72. Middle East and Africa Ulcerative Colitis Immunology Drugs Sales by Application (2018-2024) & (US$ Million)
Table 73. North America Ulcerative Colitis Immunology Drugs Sales by Country (2018-2024) & (K Pcs)
Table 74. North America Ulcerative Colitis Immunology Drugs Sales Market Share in Volume by Country (2018-2024)
Table 75. North America Ulcerative Colitis Immunology Drugs Sales by Country (2018-2024) & (US$ Million)
Table 76. North America Ulcerative Colitis Immunology Drugs Sales Market Share in Value by Country (2018-2024)
Table 77. North America Ulcerative Colitis Immunology Drugs Sales by Country (2024-2034) & (K Pcs)
Table 78. North America Ulcerative Colitis Immunology Drugs Sales Market Share in Volume by Country (2024-2034)
Table 79. North America Ulcerative Colitis Immunology Drugs Sales by Country (2024-2034) & (US$ Million)
Table 80. North America Ulcerative Colitis Immunology Drugs Sales Market Share in Value by Country (2024-2034)
Table 81. Europe Ulcerative Colitis Immunology Drugs Sales by Country (2018-2024) & (K Pcs)
Table 82. Europe Ulcerative Colitis Immunology Drugs Sales Market Share in Volume by Country (2018-2024)
Table 83. Europe Ulcerative Colitis Immunology Drugs Sales by Country (2018-2024) & (US$ Million)
Table 84. Europe Ulcerative Colitis Immunology Drugs Sales Market Share in Value by Country (2018-2024)
Table 85. Europe Ulcerative Colitis Immunology Drugs Sales by Country (2024-2034) & (K Pcs)
Table 86. Europe Ulcerative Colitis Immunology Drugs Sales Market Share in Volume by Country (2024-2034)
Table 87. Europe Ulcerative Colitis Immunology Drugs Sales by Country (2024-2034) & (US$ Million)
Table 88. Europe Ulcerative Colitis Immunology Drugs Sales Market Share in Value by Country (2024-2034)
Table 89. Asia-Pacific Ulcerative Colitis Immunology Drugs Sales by Region (2018-2024) & (K Pcs)
Table 90. Asia-Pacific Ulcerative Colitis Immunology Drugs Sales Market Share in Volume by Region (2018-2024)
Table 91. Asia-Pacific Ulcerative Colitis Immunology Drugs Sales by Region (2018-2024) & (US$ Million)
Table 92. Asia-Pacific Ulcerative Colitis Immunology Drugs Sales Market Share in Value by Region (2018-2024)
Table 93. Asia-Pacific Ulcerative Colitis Immunology Drugs Sales by Region (2024-2034) & (K Pcs)
Table 94. Asia-Pacific Ulcerative Colitis Immunology Drugs Sales Market Share in Volume by Region (2024-2034)
Table 95. Asia-Pacific Ulcerative Colitis Immunology Drugs Sales by Region (2024-2034) & (US$ Million)
Table 96. Asia-Pacific Ulcerative Colitis Immunology Drugs Sales Market Share in Value by Region (2024-2034)
Table 97. Latin America Ulcerative Colitis Immunology Drugs Sales by Country (2018-2024) & (K Pcs)
Table 98. Latin America Ulcerative Colitis Immunology Drugs Sales Market Share in Volume by Country (2018-2024)
Table 99. Latin America Ulcerative Colitis Immunology Drugs Sales by Country (2018-2024) & (US$ Million)
Table 100. Latin America Ulcerative Colitis Immunology Drugs Sales Market Share in Value by Country (2018-2024)
Table 101. Latin America Ulcerative Colitis Immunology Drugs Sales by Country (2024-2034) & (K Pcs)
Table 102. Latin America Ulcerative Colitis Immunology Drugs Sales Market Share in Volume by Country (2024-2034)
Table 103. Latin America Ulcerative Colitis Immunology Drugs Sales by Country (2024-2034) & (US$ Million)
Table 104. Latin America Ulcerative Colitis Immunology Drugs Sales Market Share in Value by Country (2024-2034)
Table 105. Middle East and Africa Ulcerative Colitis Immunology Drugs Sales by Country (2018-2024) & (K Pcs)
Table 106. Middle East and Africa Ulcerative Colitis Immunology Drugs Sales Market Share in Volume by Country (2018-2024)
Table 107. Middle East and Africa Ulcerative Colitis Immunology Drugs Sales by Country (2018-2024) & (US$ Million)
Table 108. Middle East and Africa Ulcerative Colitis Immunology Drugs Sales Market Share in Value by Country (2018-2024)
Table 109. Middle East and Africa Ulcerative Colitis Immunology Drugs Sales by Country (2024-2034) & (K Pcs)
Table 110. Middle East and Africa Ulcerative Colitis Immunology Drugs Sales Market Share in Volume by Country (2024-2034)
Table 111. Middle East and Africa Ulcerative Colitis Immunology Drugs Sales by Country (2024-2034) & (US$ Million)
Table 112. Middle East and Africa Ulcerative Colitis Immunology Drugs Sales Market Share in Value by Country (2024-2034)
Table 113. Janssen Biotech, Inc. Company Information
Table 114. Janssen Biotech, Inc. Introduction and Business Overview
Table 115. Janssen Biotech, Inc. Ulcerative Colitis Immunology Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 116. Janssen Biotech, Inc. Ulcerative Colitis Immunology Drugs Product
Table 117. Janssen Biotech, Inc. Recent Development
Table 118. Bristol-Myers Squibb Company Company Information
Table 119. Bristol-Myers Squibb Company Introduction and Business Overview
Table 120. Bristol-Myers Squibb Company Ulcerative Colitis Immunology Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 121. Bristol-Myers Squibb Company Ulcerative Colitis Immunology Drugs Product
Table 122. Bristol-Myers Squibb Company Recent Development
Table 123. AbbVie Inc. Company Information
Table 124. AbbVie Inc. Introduction and Business Overview
Table 125. AbbVie Inc. Ulcerative Colitis Immunology Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 126. AbbVie Inc. Ulcerative Colitis Immunology Drugs Product
Table 127. AbbVie Inc. Recent Development
Table 128. UCBCares Company Information
Table 129. UCBCares Introduction and Business Overview
Table 130. UCBCares Ulcerative Colitis Immunology Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 131. UCBCares Ulcerative Colitis Immunology Drugs Product
Table 132. UCBCares Recent Development
Table 133. AMGEN Company Information
Table 134. AMGEN Introduction and Business Overview
Table 135. AMGEN Ulcerative Colitis Immunology Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 136. AMGEN Ulcerative Colitis Immunology Drugs Product
Table 137. AMGEN Recent Development
Table 138. Celltrion Healthcare Company Information
Table 139. Celltrion Healthcare Introduction and Business Overview
Table 140. Celltrion Healthcare Ulcerative Colitis Immunology Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 141. Celltrion Healthcare Ulcerative Colitis Immunology Drugs Product
Table 142. Celltrion Healthcare Recent Development
Table 143. Biogen Company Information
Table 144. Biogen Introduction and Business Overview
Table 145. Biogen Ulcerative Colitis Immunology Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 146. Biogen Ulcerative Colitis Immunology Drugs Product
Table 147. Biogen Recent Development
Table 148. Genentech USA, Inc. Company Information
Table 149. Genentech USA, Inc. Introduction and Business Overview
Table 150. Genentech USA, Inc. Ulcerative Colitis Immunology Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 151. Genentech USA, Inc. Ulcerative Colitis Immunology Drugs Product
Table 152. Genentech USA, Inc. Recent Development
Table 153. ROCHE Company Information
Table 154. ROCHE Introduction and Business Overview
Table 155. ROCHE Ulcerative Colitis Immunology Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 156. ROCHE Ulcerative Colitis Immunology Drugs Product
Table 157. ROCHE Recent Development
Table 158. Pfizer Inc. Company Information
Table 159. Pfizer Inc. Introduction and Business Overview
Table 160. Pfizer Inc. Ulcerative Colitis Immunology Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2018-2024)
Table 161. Pfizer Inc. Ulcerative Colitis Immunology Drugs Product
Table 162. Pfizer Inc. Recent Development
Table 163. Key Raw Materials Lists
Table 164. Raw Materials Key Suppliers Lists
Table 165. Ulcerative Colitis Immunology Drugs Market Trends
Table 166. Ulcerative Colitis Immunology Drugs Market Drivers
Table 167. Ulcerative Colitis Immunology Drugs Market Challenges
Table 168. Ulcerative Colitis Immunology Drugs Market Restraints
Table 169. Ulcerative Colitis Immunology Drugs Distributors List
Table 170. Ulcerative Colitis Immunology Drugs Downstream Customers
Table 171. Research Programs/Design for This Report
Table 172. Key Data Information from Secondary Sources
Table 173. Key Data Information from Primary Sources
List of Figures
Figure 1. Ulcerative Colitis Immunology Drugs Product Picture
Figure 2. Global Ulcerative Colitis Immunology Drugs Market Size, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Ulcerative Colitis Immunology Drugs Market Size Status and Outlook (2018-2034) & (US$ Million)
Figure 4. Global Ulcerative Colitis Immunology Drugs Sales Status and Outlook (2018-2034) & (K Pcs)
Figure 5. Product Picture of Adalimumab
Figure 6. Global Adalimumab Sales YoY Growth (2018-2034) & (K Pcs)
Figure 7. Product Picture of Certolizumab Pegol
Figure 8. Global Certolizumab Pegol Sales YoY Growth (2018-2034) & (K Pcs)
Figure 9. Product Picture of Tofacitinib
Figure 10. Global Tofacitinib Sales YoY Growth (2018-2034) & (K Pcs)
Figure 11. Product Picture of Etanercept
Figure 12. Global Etanercept Sales YoY Growth (2018-2034) & (K Pcs)
Figure 13. Product Picture of Golimumab
Figure 14. Global Golimumab Sales YoY Growth (2018-2034) & (K Pcs)
Figure 15. Product Picture of Abatacept
Figure 16. Global Abatacept Sales YoY Growth (2018-2034) & (K Pcs)
Figure 17. Product Picture of Infliximab
Figure 18. Global Infliximab Sales YoY Growth (2018-2034) & (K Pcs)
Figure 19. Product Picture of Others
Figure 20. Global Others Sales YoY Growth (2018-2034) & (K Pcs)
Figure 21. Global Ulcerative Colitis Immunology Drugs Sales by Type (2018-2034) & (US$ Million)
Figure 22. Global Ulcerative Colitis Immunology Drugs Sales Market Share by Type in 2022 & 2034
Figure 23. North America Ulcerative Colitis Immunology Drugs Sales Market Share in Volume by Type in 2022
Figure 24. North America Ulcerative Colitis Immunology Drugs Sales Market Share in Value by Type in 2022
Figure 25. Europe Ulcerative Colitis Immunology Drugs Sales Market Share in Volume by Type in 2022
Figure 26. Europe Ulcerative Colitis Immunology Drugs Sales Market Share in Value by Type in 2022
Figure 27. Asia-Pacific Ulcerative Colitis Immunology Drugs Sales Market Share in Volume by Type in 2022
Figure 28. Asia-Pacific Ulcerative Colitis Immunology Drugs Sales Market Share in Value by Type in 2022
Figure 29. Latin America Ulcerative Colitis Immunology Drugs Sales Market Share in Volume by Type in 2022
Figure 30. Latin America Ulcerative Colitis Immunology Drugs Sales Market Share in Value by Type in 2022
Figure 31. Middle East and Africa Ulcerative Colitis Immunology Drugs Sales Market Share in Volume by Type in 2022
Figure 32. Middle East and Africa Ulcerative Colitis Immunology Drugs Sales Market Share in Value by Type in 2022
Figure 33. The 5 and 10 Largest Manufacturers in the World: Market Share by Ulcerative Colitis Immunology Drugs Sales in 2022
Figure 34. The 5 and 10 Largest Manufacturers in the World: Market Share by Ulcerative Colitis Immunology Drugs Revenue in 2022
Figure 35. Ulcerative Colitis Immunology Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 36. Product Picture of Rheumatoid Arthritis
Figure 37. Global Rheumatoid Arthritis Sales YoY Growth (2018-2034) & (K Pcs)
Figure 38. Product Picture of Crohn's Disease(CD)
Figure 39. Global Crohn's Disease(CD) Sales YoY Growth (2018-2034) & (K Pcs)
Figure 40. Product Picture of Ankylosing Spondylitis(AS)
Figure 41. Global Ankylosing Spondylitis(AS) Sales YoY Growth (2018-2034) & (K Pcs)
Figure 42. Product Picture of Psoriasis(Ps)
Figure 43. Global Psoriasis(Ps) Sales YoY Growth (2018-2034) & (K Pcs)
Figure 44. Product Picture of Ulcerative Colitis(UC)
Figure 45. Global Ulcerative Colitis(UC) Sales YoY Growth (2018-2034) & (K Pcs)
Figure 46. Global Ulcerative Colitis Immunology Drugs Sales by Application (2018-2034) & (US$ Million)
Figure 47. Global Ulcerative Colitis Immunology Drugs Sales Market Share by Application in 2022 & 2034
Figure 48. North America Ulcerative Colitis Immunology Drugs Sales Market Share in Volume by Application in 2022
Figure 49. North America Ulcerative Colitis Immunology Drugs Sales Market Share in Value by Application in 2022
Figure 50. Europe Ulcerative Colitis Immunology Drugs Sales Market Share in Volume by Application in 2022
Figure 51. Europe Ulcerative Colitis Immunology Drugs Sales Market Share in Value by Application in 2022
Figure 52. Asia-Pacific Ulcerative Colitis Immunology Drugs Sales Market Share in Volume by Application in 2022
Figure 53. Asia-Pacific Ulcerative Colitis Immunology Drugs Sales Market Share in Value by Application in 2022
Figure 54. Latin America Ulcerative Colitis Immunology Drugs Sales Market Share in Volume by Application in 2022
Figure 55. Latin America Ulcerative Colitis Immunology Drugs Sales Market Share in Value by Application in 2022
Figure 56. Middle East and Africa Ulcerative Colitis Immunology Drugs Sales Market Share in Value by Application in 2022
Figure 57. Key Raw Materials Price
Figure 58. Ulcerative Colitis Immunology Drugs Manufacturing Cost Structure
Figure 59. Ulcerative Colitis Immunology Drugs Industrial Chain Analysis
Figure 60. Channels of Distribution
Figure 61. Distributors Profiles
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries